gms | German Medical Science

57. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

11. bis 14.05.2006, Essen

Expression of lymphangiogenesis-related factors in glioblastomas – a novel aspect in glioma angiogenesis

Expression des Lymphangiogenese-assoziierter Faktoren in Glioblastomen – neue Aspekte der Angiogenese in Gliomen

Meeting Abstract

  • corresponding author S. Grau - Neurochirurgische Klinik Klinikum Großhadern, LMU München
  • F. Trillsch - Neurochirurgische Klinik Klinikum Großhadern, LMU München
  • N. Thon - Neurochirurgische Klinik Klinikum Großhadern, LMU München
  • J.-C. Tonn - Neurochirurgische Klinik Klinikum Großhadern, LMU München
  • P. Nelson - Medizinische Klinik Innenstadt, LMU München
  • R. Goldbrunner - Neurochirurgische Klinik Klinikum Großhadern, LMU München

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 57. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie. Essen, 11.-14.05.2006. Düsseldorf, Köln: German Medical Science; 2006. DocP 05.61

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dgnc2006/06dgnc278.shtml

Veröffentlicht: 8. Mai 2006

© 2006 Grau et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: Malignant gliomas are highly vascularized tumors. The vascular endothelial growth factor receptor-2 (VEGFR2) system has been established as a key regulator for glioma neoangiogenesis. VEGFR3 is indispensable in embryonic vasculogenesis and its later expression usually restricted to lymphatic endothelium. However, there is growing evidence for a role of VEGFR3 in tumor malignancy and metastasis. Presence and role of VEGFR3, its ligands VEGF-C and -D as well as lymphatic markers like podoplanin has not been investigated in malignant gliomas up to date. Here we report the expression of these receptors and markers in human gliomas depending on tumor malignancy.

Methods: Samples of human glioblastoma (n=18), low grade astrocytoma (n=6) and non neoplastic brain (n=3) were investigated for expression of VEGFR3, VEGF-C and VEGF-D on mRNA and protein level by use of real time PCR, immunohistochemistry and Western blot analysis.

Results: In immunohistochemistry 18/18 glioblastomas showed a high expression of VEGFR3, VEGF-C and VEGF-D. VEGFR3 was mainly present on tumor-vessel endothelium, however, in areas of high vessel density also numerous stromal cells stained positive. VEGF-C and -D was expressed strongest in areas of high vessel density. In low grade astrocytomas, VEGFR3 was positive in single endothelial cells of some larger vessels in 2/6 samples while being absent in normal brain. Podoplanin was detected in all glioblastomas. On mRNA level, transcripts for VEGFR3 and podoplanin were significantly elevated in 6/6 glioblastomas compared to low grade astrocytomas and normal brain (p<0.01). Western blot analysis showed a high amount of VEGF-C and -D as well as VEGFR3 in 6/6 glioblastomas while being absent in normal brain and low grade tumors.

Conclusions: The presence of VEGFR3 as well as its ligands VEGF-C and -D indicates the presence of an additional angiogenic signaling system. This may lead to a more profound understanding of tumor angiogenesis and glioma progression. Moreover, this data might influence future concepts of antiangiogenic therapy.